Increasing fluid overload can reduce the intestinal absorption of diuretics, compromising bioavailability.1-3 Through subcutaneous administration, FUROSCIX is able to deliver at-home, IV-equivalent diuresis with 99.6% absolute bioavailability—even in the presence of fluid overload.1
Urine output was seen within 60 minutes1,2
0-8 H
0-24 H
Open-label, crossover study design1:
Furosemide can cause dehydration and azotemia. If increasing azotemia and oliguria occur during treatment of severe progressive renal disease, furosemide should be discontinued.
*
90% confidence interval of 94.8-104.8. The design of the device used in this study was different from the current FUROSCIX On-Body Infusor, but it used the same administration profile.
†
Urine output over the periods of 0 to 8 hours and 0 to 24 hours following administration of 80-mg furosemide by 5-hour subcutaneous infusion with FUROSCIX, or IV administration of 2 doses of 40 mg 2 hours apart. Time 0 indicates the start of diuresis therapy.
‡
Based on mean +/- SD 30-minute plasma concentration of 600 (± 209) ng/mL.1
SD=standard deviation.